Blood test to spot Alzheimer's before symptoms occur

Image
IANS London
Last Updated : May 04 2019 | 2:25 PM IST

Researchers have developed a new test that could help doctors detect Alzheimer's disease eight years before the first symptoms occur.

Using current techniques, Alzheimer's disease, the most frequent cause of dementia, can only be detected once the typical plaques have formed in the brain.

At this point, therapy seems no longer possible. However, the first changes caused by Alzheimer's take place on the protein level up to 20 years sooner.

"Once amyloid plaques have formed, it seems that the disease can no longer be treated," said study co-author Andreas Nabers from Ruhr-University Bochum in Germany.

In Alzheimer's patients, the amyloid beta protein folds incorrectly due to pathological changes long before the first symptoms occur.

A team of researchers headed by Klaus Gerwert from Ruhr-University Bochum successfully diagnosed this misfolding using a simple blood test. As a result, the disease could be detected approximately eight years before the first clinical symptoms occur.

But experiments showed that the test was not suitable for clinical applications as the test provided false positive diagnoses for nine per cent of the study participants.

In order to increase the number of correctly identified Alzheimer's cases, the researchers have now introduced the two-tier diagnostic method.

To this end, they use the original blood test to identify high-risk individuals. Subsequently, they add a dementia-specific biomarker, namely tau protein, to run further tests with those test participants whose Alzheimer's diagnosis was positive in the first step.

If both biomarkers show a positive result, there is a high likelihood of Alzheimer's disease, said the study published in the journal Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.

"Through the combination of both analyses, 87 of 100 Alzheimer's patients were correctly identified in our study," Gerwert said.

"Now, new clinical studies with test participants in very early stages of the disease can be launched," Gerwert added.

--IANS

bu/gb/bg

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 04 2019 | 2:18 PM IST

Next Story